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Abstract 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) affecting most commonly the Caucasian population. Nitric oxide (NO) is a biological 
signaling and effector molecule and is especially important during inflammation. Inducible 
nitric oxide synthase (iNOS) is one of the three enzymes responsible for generating NO. It has 
been reported that there is an excessive production of NO in MS concordant with an increased 
expression of iNOS in MS lesions. This study investigated the role of a bi-allelic 
tetranucleotide polymorphism located in the promoter region of the human iNOS (NOS2A) 
gene in MS susceptibility. A group of MS patients (n = 101) were genotyped and compared to 
an age- and sex-matched group of healthy controls (n = 101). The MS group was subdivided 
into three subtypes, namely relapsing-remitting MS (RR-MS), secondary-progressive MS 
(SP-MS) and primary-progressive MS (PP-MS). Results of a chi-squared analysis and a 
Fisher’s exact test revealed that allele and genotype distributions between cases and controls 
were not significantly different for the total population ( 2 = 3.4, Pgenotype = 0.15; 2 = 3.4, 
Pallele = 0.082) and for each subtype of MS (P > 0.05). This suggests that there is no direct 
association of this iNOS gene variant with MS susceptibility.  
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1. Introduction 
Multiple sclerosis (MS) is a serious disabling neurological disorder affecting young 
Caucasian individuals, with an age of onset typically ranging from 18 to 40 years. Females 
account for approximately 60% of MS cases [27.] with the incidence of MS in Northern 
Europe, Canada, and the Northern United States being approximately 10 new cases per year 
per 100,000 persons (between the ages of 20 and 50 years). With the exception of trauma, MS 
remains the most frequent cause of neurological disability for young adults. The central 
nervous system (CNS) in MS is affected with patches of myelin degeneration produced by 
multifocal inflammatory events. The disease is disseminated in time and space, with MS 
classified into types, based on the clinical course namely relapsing-remitting MS (RR-MS), 
secondary-progressive MS (SP-MS), and primary-progressive MS (PP-MS) [25.]. Studies 
indicate that MS has a genetic component with 30% of monozygotic twins developing the 
disease compared to only 4.7% in dizygotic twins [24.]. The HLA gene complex has been 
shown to be associated with MS [9.], but the HLA contribution does not appear to explain all 
the susceptibility. Other genes have been found to be related with disease severity including 
the interleukin-1 receptor antagonist (IL-1ra) gene [7.], and Fc-receptor (Fc R) genes [19.]. 
Nitric oxide (NO) is a free radical agent with wide biological functions. It is produced by a 
group of enzymes called nitric oxide synthase (NOS). NOS catalyses the production of NO 
and -citrulline from -arginine, O2 and NADPH. There are three isoforms of NOS: neuronal 
NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). The last isoform is a 
calcium independent enzyme responsible for producing high output and long-lasting release 
of NO, exceeding the NO production level of nNOS and eNOS isoforms. Expression of iNOS 
is under the regulation of several cytokines such as interferon gamma (IFN- ), tumor necrosis 
factor (TNF- ), and interleukin 1 beta (IL-1 ) [10.] and its function is part of the 
macrophage-mediated response to infectious agents. Activated macrophages residing within 
MS brain lesions have been demonstrated [1.]. Within the cerebrospinal fluid (CSF), NO 
products have been found at a higher concentration in MS patients compared to healthy 
control subjects [20.]. Furthermore, increased iNOS activity has been detected in the CSF of 
MS patients with high NO concentration levels correlating with disease activity [6. and 8.]. In 
animals with experimental allergic encephalomyelitis (EAE), a model of MS, increased CNS 
mRNA levels of iNOS have been demonstrated along with high levels of cytokines, 
particularly involved in iNOS activation [23.]. Interestingly, this up-regulation of iNOS in 
EAE is concomitant with a decrease in Ca2+-dependent NOS activity of eNOS and nNOS 
[26.]. In a human MS study, iNOS mRNA and iNOS enzymatic activity have been detected in 
MS plaque lesions [15.]. Inducible NOS activity resides in activated and differentiated 
monocytes in MS patients suggesting a role for monocyte iNOS in the autoimmune response 
underlying disease pathogenesis [16.]. The activity of iNOS has detrimental effects on 
oligodendrocytes, cells responsible for the myelination of neurons in the CNS [17.]. 
Nitric oxide might play a critical role in the pathogenesis of MS, and alterations of the iNOS 
gene could possibly have an impact on the disease. The human iNOS (NOS2A) gene has been 
localized to chromosome 17q11-2-q12, a locus close to a region linked with MS on 
chromosome 17q21-q22 [11.]. The gene consists of 27 exons and is about 40 kb in length 
[28.]. To determine the possible involvement of polymorphisms of iNOS in the pathogenesis 
of MS, a bi-allelic tetranucleotide polymorphism in the promoter region of the human iNOS 
gene has been examined by employing an association study approach in a group of MS 
patients and age/sex-matched controls. 
2. Materials and methods 
2.1. Subjects 
The study protocol was approved by Griffith University’s Ethics Committee for 
experimentation on humans. The case-control sample consisted of 101 MS patients and 101 
healthy controls, matched for ethnicity (Caucasian), sex and age (±5 years). The MS patients 
were recruited from the Multiple Sclerosis Clinic at the Royal Brisbane and Women’s 
Hospital, all from the South East Queensland region. The MS group consisted of 74% females 
and 26% males and was subdivided into three clinical subtypes: RR-MS, SP-MS, and PP-MS 
with frequencies of 42, 35, and 24%, respectively. The control group was also obtained from 
the South East Queensland region through the Genomics Research Centre, Southport, with 
each control age (±5 years), sex, and ethnicity matched to the affected population. All 
individuals gave informed consent before participating in the research. Genomic DNA was 
extracted from peripheral blood using a standard salting-out protocol. 
2.2. Genotyping 
DNA was extracted from frozen whole blood by a standard salting-out procedure and used as 
a template to generate polymerase chain reaction (PCR) products for genotyping. Within the 
5′-flanking DNA of the iNOS gene there is a AAAT/AAAAAT repeat sequence extending 
from −756 to −716 bp 5′ to the main TATA-directed transcription initiation site [22.]. Primers 
specific for this bi-allelic tetranucleotide repeat polymorphism located between −891 to 
−575 bp of the iNOS gene were used to perform PCR (5′-TGG TGC ATG CCT GTA GTC C-
3′ for the forward primer and 5-GAG GCC TCT GAG ATG TTG GTC-3′ for the reverse 
primer) [3.]. They were purchased from GeneWorks. The forward primer was fluorescently 
labeled with 5-carboxyfluorescein (FAM) dye. The PCR was performed with a PCR 
thermocycler machine (Gene Amp PCR System 9700; Applied Biosystems) with the 
following singleplex reaction: 1 unit of Taq polymerase, 0.2 M of each primers, 7.5 l of 
buffer (MasterAmp™ 2X PCR PreMix K), 25 ng of genomic DNA made to a final volume of 
15 l with sterile distilled water. The cycle parameters were as follows: 1 cycle at 94 °C for 
4 min, followed by 40 cycles for 1 min at 94 °C and 1 min at 60 °C, and 1 cycle for final 
extension for 2 min at 72 °C. 
All PCR products were then electrophoresed in ethidium-bromide-stained 2% agarose gels. 
Capillary electrophoresis was performed on an ABI 310 Genetic Analyser. Results were 
analyzed using GENOTYPER® software (Version 2.1; PE Biosystems). The accuracy and 
reproducibility of automated sizing of the fragments were confirmed by randomly chosen 
repeated analyses of identical samples. 
2.3. Statistical analysis 
Allele and genotype frequencies were compared using standard chi-square (independence) 
analysis and the Fisher’s exact test, implemented in the SPSS program. Power estimates 
indicated that if the iNOS tetranucleotide polymorphism were to directly confer a two-fold 
increase in relative risk of MS, the case and control groups used in this study were of 
sufficient size to have >80% power to detect a significant association at the 0.05 level. 
3. Results 
The size of the DNA fragments amplified for the iNOS variant were 313 and 317 bp 
corresponding to the two alleles: no insertion (n) and insertion (i). Results for genotype and 
allele frequencies are provided in Table 1 and Table 2. Genotype frequencies for the control 
and the MS groups conformed to Hardy Weinberg equilibrium expectations reducing the risk 
of error during genotyping. The proportion of the alleles for the control population was 
similar to others found in independent studies [13. and 18.].  





Allele: n, no AAAT insert; i, presence of the AAAT insert. 
a Fisher’s exact test. 
 





Allele: n, no AAAT insert; i, presence of the AAAT insert; 
Results for the Fisher’s exact test and the chi squared analysis indicate that there is no 
significant difference between MS patients and the control population, either for genotype 
frequencies (P = 0.15) or for allele frequencies ( 2 = 3.03, P = 0.0819). 
 
Table 3. Genotype frequencies of iNOS insert for different subtypes of MS in Australian 
multiple sclerosis patients and controls  
 
 
Fisher’s exact test. 
  *P=0.44 
  **P=0.77 
  ***P=0.46 
 
Table 4. Allele frequencies of iNOS insert for different subtypes of MS in Australian multiple 
sclerosis patients and controls 
 
 
Fisher’s exact test. 
  *P=0.35 
  **P=0.59 
  ***P=0.49 
 
Results for the Fisher’s exact test showed no significant differences between the subtypes of 
MS and the control population for both genotype frequencies or for allele frequencies (Tables 
3 and 4). 
4. Discussion 
MS is a complex neurological disease, with genetic factors believed to play a significant role 
in susceptibility. Several genes have been found to be associated with the disease including 
the Human Leukocyte Antigen (HLA) haplotypes, HLA DRB1*1501, DQA1*0102, DQB1 
0602 [9.], the Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene [14.], and the 
osteopontin (OPN) gene [21.]. Infiltrating macrophages within MS plaque lesions produce 
NO products generated by iNOS gene activity. In the present study, we investigated a 
tetranucleotide repeat polymorphism in the iNOS gene promoter in patients with different 
subgroups of MS and compared it with the genotypes of healthy controls with no history of 
MS. This study indicated no association of the tested iNOS polymorphism in an Australian 
MS population. Our findings support those obtained in studies on an ethnically-different 
Swedish population [18.] and Spanish population [4.], which showed no linkage or 
association of the same iNOS promoter marker polymorphism with MS. Despite these 
findings, it is still possible that NOS is implicated in MS susceptibility. NO is a potent 
mediator of inflammatory responses and can lead to the formation of new epitopes by S-
nitrosylation of cysteine residues of myelin proteins in MS plaques. Antibodies for such 
epitopes were found in different clinical forms of MS [5.]. Furthermore, IFN- , a drug used 
for MS therapy, is thought to be a selective inhibitor of human glial iNOS [12.]. Although the 
iNOS tetranucleotide promoter polymorphism did not show association with MS in the 
present study, it is possible that an alteration of iNOS gene activity through mutation or 
polymorphism may still contribute to MS susceptibility. Interestingly, very recent single 
nucleotide polymorphism studies in MS using pedigree disequilibrium test data have provided 
some evidence for NOS2A (iNOS) involvement, and linkage between a different NOS2A 
promoter polymorphism marker (CCTTT)n and MS DR2 positive families was also 
demonstrated [2.].  
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